## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

## LISTING OF CLAIMS:

1. (original): A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]:

$$R^{1}$$
 $N$ 
 $R^{5}$ 
 $R^{3}$ 
 $N$ 
 $R^{4}$ 
 $R^{4}$ 

(wherein R<sup>1</sup> and R<sup>2</sup> are the same or different, and independently are hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl, hydroxy-C<sub>1-6</sub>alkyl, cyano-C<sub>1-6</sub>alkyl, carbamoyl-C<sub>1-6</sub>alkyl or di(C<sub>1-6</sub>alkyl)amino-C<sub>1-6</sub>alkyl, cyano, carbamoyl or aryl;

 $R^3$  is hydrogen,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkyl- $C_{1-6}$ alkyl, halogen,  $C_{1-6}$ alkoxy,  $C_{3-7}$ cycloalkyloxy,  $C_{1-6}$ alkylthio or -N( $R^6$ ) $R^7$ ;

R<sup>4</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl or C<sub>3-7</sub>cycloalkyl-C<sub>1-6</sub>alkyl;

 $R^5$  is hydrogen,  $C_{1\text{-}6}$ alkyl, aryl- $C_{1\text{-}6}$ alkyl or carbamoyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of

halogen,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylthio,  $C_{1-6}$ alkylsulfinyl,  $C_{1-6}$ alkylsulfonyl, cyano, nitro, hydroxy,  $-CO_2R^8$ ,  $-C(=O)R^9$ ,  $-CONR^{10}R^{11}$ ,  $-OC(=O)R^{12}$ ,  $-NR^{13}CO_2R^{14}$ ,  $-S(=O)_rNR^{15}R^{16}$ , trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and  $-N(R^{17})R^{18}$ ;

 $R^8$  and  $R^{14}$  are the same or different, and independently are hydrogen or  $C_{1-5}$ alkyl,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl,  $C_{1-5}$ alkyl, aryl or aryl- $C_{1-5}$ alkyl;

 $R^6$ ,  $R^7$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  and  $R^{18}$  are the same or different, and independently are hydrogen,  $C_{1-6}$ alkyl or  $C_{3-7}$ cycloalkyl;

r is 1 or 2) or individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 2. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein  $R^3$  is  $C_{1-6}$ alkyl;  $R^4$  is hydrogen or  $C_{1-6}$ alkyl;  $R^5$  is hydrogen or  $C_{1-6}$ alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen,  $C_{1-3}$ alkyl,  $C_{1-3}$ alkoxy,  $C_{1-3}$ alkylthio, trifluoromethyl, trifluoromethoxy and  $-N(R^{17})R^{18}$  (wherein  $R^{17}$  and  $R^{18}$  are the same or different, and independently are hydrogen or  $C_{1-3}$ alkyl);  $R^1$ ,  $R^2$  and  $R^4$  are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.
- 3. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein  $R^3$  is  $C_{1-3}$ alkyl;  $R^5$  is hydrogen or  $C_{1-3}$ alkyl; Ar is phenyl which phenyl is

Preliminary Amendment

Appln. No.: National Stage of PCT/JP2005/000323

substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and  $C_{1-3}$ alkyl;  $R^1$ ,  $R^2$  and  $R^4$  are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

- 4. (currently amended): An antagonist for CRF receptors, comprising a triazacyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1 any one of claims 1 to 3, as an active ingredient.
- 5. (currently amended): Use of a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to <u>claim 1 any one of claim 1 to 3</u>, for the manufacture of a therapeutic agent as an antagonist for CRF receptors.